ANN ARBOR (AP) — A degenerative eye disease slowly robbed Roger Pontz of his vision.
Diagnosed with retinitis pigmentosa as a teenager, Pontz has been almost completely blind for years. Now, thanks to a high-tech procedure that involved the surgical implantation of a “bionic eye,” he has regained enough of his eyesight to catch small glimpses of his wife, grandson and cat.
“It’s awesome. It’s exciting — seeing something new every day,” Pontz said during a recent appointment at the University of Michigan Kellogg Eye Center. The 55-year-old former competitive weightlifter and factory worker is one of four people in the U.S. to receive an artificial retina since the Food and Drug Administration signed off on its use last year.
The facility in Ann Arbor has been the site of all four such surgeries since FDA approval. A fifth is scheduled for next month.
Retinitis pigmentosa is an inherited disease that causes slow but progressive vision loss due to a gradual loss of the light-sensitive retinal cells called rods and cones. Patients experience loss of side vision and night vision, then central vision, which can result in near blindness.
Not all of the 100,000 or so people in the U.S. with retinitis pigmentosa can benefit from the bionic eye. An estimated 10,000 have vision low enough, said Dr. Brian Mech, an executive with Second Sight Medical Products Inc., the Sylmar, Calif.-based company that makes the device. Of those, about 7,500 are eligible for the surgery.
The artificial implant in Pontz’s left eye is part of a system developed by Second Sight that includes a small video camera and transmitter housed in a pair of glasses.
Images from the camera are converted into a series of electrical pulses that are transmitted wirelessly to an array of electrodes on the surface of the retina. The pulses stimulate the retina’s remaining healthy cells, causing them to relay the signal to the optic nerve.